$3.36
7.01% day before yesterday
Nasdaq, Jan 02, 10:02 pm CET
ISIN
CH0329023102
Symbol
ACIU

AC Immune SA Stock price

$3.36
+0.59 21.30% 1M
+1.34 66.34% 6M
+0.22 7.01% YTD
+0.51 17.89% 1Y
+1.32 64.71% 3Y
-1.96 36.84% 5Y
-12.30 78.54% 10Y
-12.30 78.54% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.22 7.01%
ISIN
CH0329023102
Symbol
ACIU
Industry

Key metrics

Basic
Market capitalization
$332.5m
Enterprise Value
$201.4m
Net debt
positive
Cash
$137.0m
Shares outstanding
100.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
60.2 | 58.7
EV/Sales
36.5 | 35.5
EV/FCF
negative
P/B
4.2
Financial Health
Equity Ratio
48.6%
Return on Equity
-45.4%
ROCE
-99.7%
ROIC
330.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$5.5m | $5.7m
EBITDA
$-89.3m | $20.6m
EBIT
$-92.3m | $-63.9m
Net Income
$-90.8m | $-90.5m
Free Cash Flow
$-60.2m
Growth (TTM | estimate)
Revenue
-89.3% | -83.6%
EBITDA
-101.4% | 132.5%
EBIT
-95.9% | 3.4%
Net Income
-80.3% | -40.8%
Free Cash Flow
-210.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,617.1% | 363.7%
EBIT
-1,671.4%
Net
-1,643.9% | -1,597.8%
Free Cash Flow
-1,091.1%
More
EPS
$-0.9
FCF per Share
$-0.6
Short interest
7.5%
Employees
153
Rev per Employee
$230.0k
Show more

Is AC Immune SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

AC Immune SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AC Immune SA forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AC Immune SA forecast:

Buy
89%
Hold
11%

Financial data from AC Immune SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5.52 5.52
89% 89%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
17% 17%
257%
- Research and Development Expense 78 78
0% 0%
1,409%
-89 -89
101% 101%
-1,617%
- Depreciation and Amortization 3 3
9% 9%
54%
EBIT (Operating Income) EBIT -92 -92
96% 96%
-1,672%
Net Profit -91 -91
80% 80%
-1,644%

In millions USD.

Don't miss a Thing! We will send you all news about AC Immune SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AC Immune SA Stock News

Positive
Seeking Alpha
19 days ago
AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to potentially establish a registration study as a key value-driving catalyst. The company benefits from a robust pipeline, including partnerships with Takeda and Johnson & Johnson, and significant mi...
Neutral
GlobeNewsWire
23 days ago
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.
Neutral
GlobeNewsWire
2 months ago
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn Cash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestones P...
More AC Immune SA News

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Head office Switzerland
CEO Andrea Pfeifer
Employees 153
Founded 2003
Website www.acimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today